Kintara Therapeutics Inc
For the period ended Jun 30, 2024. Filed Oct 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Oct 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| KINTARA THERAPEUTICS, INC. | |||
| Dated: October 7, 2024 | By: | /s/ Robert E. Hoffman | |
|---|---|---|---|
| Name: | Robert E. Hoffman | ||
| Title: | Chief Executive Officer and Interim Chief Financial Officer(Principal Executive Officer and Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Robert E. Hoffman | Chief Executive Officer, Interim Chief Financial Officer, Director | October 7, 2024 |
| Robert E. Hoffman | (Principal Executive Officer and Principal Financial and Accounting Officer) | |
| /s/ Tamara A. Favorito | Director | October 7, 2024 |
| Tamara A. Favorito | ||
| /s/ Robert J. Toth | Director | October 7, 2024 |
| Robert J. Toth | ||
| /s/ Laura Johnson | Director | October 7, 2024 |
| Laura Johnson | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.